MOUNTAIN VIEW, Calif., Sept. 28, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (ALXA) announced today that it has retained Guggenheim Securities, LLC to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions.
"We continue to see long-term opportunities for our Staccato inhaled drug technology, especially in light of the positive responses from physicians and patients who have used our lead product, ADASUVE," said Thomas B. King, President and CEO of Alexza. "Our Board is focused on evaluating additional options that may enhance or accelerate the value that we believe is inherent in an approved technology-platform product, which has been successfully screened for numerous drugs as a novel delivery method that enables pharmacokinetics similar to intravenous administration. Given this strength of our Staccato technology, we believe now is the appropriate time to explore strategic alternatives."
Repeat: "Our Board is focused on evaluating additional options that may enhance or accelerate the value that we believe is inherent". I hope for action on this soon. Shares are undervalued and I am significantly underwater for years but not letting go. Hopefully with the manufacturing shutdown plan in place, the stock will recover as running costs dramatically reduce....but the "inherent value" is another issue to reach a level for a real return on investment. There must be some interested parties in this proven technology given positive real world feedback.
